Surgical Valvuloplasty for Congenital Mitral Insufficiency

Sponsor
Hong Liu (Other)
Overall Status
Unknown status
CT.gov ID
NCT03567668
Collaborator
(none)
200
1
84
2.4

Study Details

Study Description

Brief Summary

Congenital mitral insufficiency is one of the most common valvular diseases in the pediatric population worldwide, carrying a high morbidity and mortality risk if not treated immediately and properly. Given that mitral replacement likely increased risk of cardiac dysfunction and mitral reoperation, mitral repair is the currently preferred surgical strategy in the majority of pediatric patients with mitral insufficiency. Unfortunately, previous evidences demonstrated the long-term hemodynamic alteration in response to significant mitral regurgitant might lead to a reversible or irreversible pulmonary vascular remodeling regardless of concomitant other cardiac malformations, which is associated with increased risk of morbidity and mortality following the surgery. Currently available researches mainly focused the association of pulmonary vascular pressures with risk of mortality and morbidity on adult rheumatic or degenerative mitral insufficiency; however, knowledge is still lacking regarding pediatric population with congenital mitral insufficiency. The investigator wil assess the relationship between baseline sPAP and risk of operative morbidity and mortality.

Condition or Disease Intervention/Treatment Phase
  • Procedure: mitral valvuloplasty

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Individualized Surgical Repair for Congenital Mitral Insufficiency in Infants and Children
Actual Study Start Date :
Jan 1, 2012
Anticipated Primary Completion Date :
Dec 31, 2018
Anticipated Study Completion Date :
Dec 31, 2018

Outcome Measures

Primary Outcome Measures

  1. Recurrence-free survival [Postoperatively; until five years after initial operation]

    recurrence-free survival is defined as free of more than moderate mitral valve regurgitation

Secondary Outcome Measures

  1. Postoperative complications [Postoperatively, until one month after initial operation]

    All postoperative complications and their treatment will be registered.

Eligibility Criteria

Criteria

Ages Eligible for Study:
3 Months to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • evidence of normal or preserved left ventricular systolic function (defined as left ventricular ejection fraction [LVEF] >50%);

  • native mitral regurgitation of grade moderate or greater;

  • with or without systemic-to-pulmonary shunting necessitating concomitant surgical repairs, regardless of pulmonary arterial pressure or pulmonary artery wedge pressure.

Exclusion Criteria:
  • functional single ventricle;

  • rheumatic mitral diseases;

  • Eisenmenger syndrome;

  • aortopathy, transposition of the great arteries, obstructions of ventricular outflow tract, malignant arrhythmias, cardiomyopathy, microbiological identification of infective endocarditis;

  • a history of pericardiotomy or intervention therapy.

Contacts and Locations

Locations

Site City State Country Postal Code
1 TEDA International Cardiovascular Hospital Tianjin Tianjin China 300457

Sponsors and Collaborators

  • Hong Liu

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Hong Liu, Clinical Investigator, Nanjing Medical University
ClinicalTrials.gov Identifier:
NCT03567668
Other Study ID Numbers:
  • TedaICH-MVP
First Posted:
Jun 26, 2018
Last Update Posted:
Jun 26, 2018
Last Verified:
Jun 1, 2018
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 26, 2018